

Synthesis of Conformationally Constrained 5-Fluoro- and 5-Hydroxymethanopyrrolidines. Ring-Puckered Mimics of *Gauche*- and *Anti*-3-Fluoro- and 3-Hydroxypyrrolidines

Grant R. Krow,^{*,†} Ram Edupuganti,[†] Deepa Gandla,[†] Fang Yu,[†] Matthew Sender,[†] Philip E. Sonnet,[†] Michael J. Zdilla,[†] Charles DeBrosse,[†] Kevin C. Cannon,[§] Charles W. Ross, III,[‡] Amit Choudhary,[‡] Matthew D. Shoulders,[#] and Ronald T. Raines^{||}

[†]Department of Chemistry, Temple University, Philadelphia, Pennsylvania 19122, United States


[‡]Department of Medicinal Chemistry, Merck Research Laboratories, Merck & Co., Inc., West Point, Pennsylvania 19486-004, United States

[§]Department of Chemistry, Pennsylvania State University, Abington, Pennsylvania, 19001, United States

^{||}Departments of Chemistry and Biochemistry, [‡]Graduate Program in Biophysics, and [#]Department of Chemistry, University of Wisconsin–Madison, Madison, Wisconsin 53706, United States


S Supporting Information

ABSTRACT: *N*-Acetylmethanopyrrolidine methyl ester and its four 5-*syn*/*anti*-fluoro and hydroxy derivatives have been synthesized from 2-azabicyclo[2.2.0]hex-5-ene, a 1,2-dihydropyridine photoproduct. These conformationally constrained mimics of idealized C^β-*gauche* and C^β-*anti* conformers of pyrrolidines were prepared in order to determine the inherent bridge bias and subsequent heteroatom substituent effects upon *trans*/*cis* amide preferences. The bridgehead position and also the presence of *gauche*(*syn*)/*anti*-5-fluoro or 5-hydroxy substituents have minimal influence upon the *K*_{T/C} values of *N*-acetamide conformers in both CDCl₃ (43–54% *trans*) and D₂O (53–58% *trans*). *O*-Benzoylation enhances the *trans* amide preferences in CDCl₃ (65% for a *syn*-OBz, 61% for an *anti*-OBz) but has minimal effect in D₂O. The synthetic methods developed for *N*-BOC-methanopyrrolidines should prove useful in the synthesis of more complex derivatives containing α-ester substituents. The *K*_{T/C} results obtained in this study establish baseline amide preferences that will enable determination of contributions of α-ester substituents to *trans*-amide preferences in methanopyrrolines.



INTRODUCTION

The ability of amides to exist as *cis*–*trans* isomers has important implications for protein structure and function.¹ The particular behavior of amides derived from the secondary amine proline has engendered much interest in this regard because of the importance of proline *cis*–*trans* isomerization to biological functions² and structure of proteins.³ There is an emerging interest in bioengineering applications of proline and substituted prolines.^{4–6}




N-Acetylproline methyl ester (Pro) **1** not only is present as a mixture of *cis*–*trans* isomers but also exists in a variety of ring conformations. Two of these in which C^γ experiences a large out-of-plane displacement are major,⁷ and we refer to them as C^γ-*endo*

(C^γ-*pucker* toward the ester) and C^γ-*exo* (C^γ-*pucker* away from the ester). Substituents at C^γ, as in (2*S*,4*S*)-4-fluoroproline (flp) **2** and (2*S*,4*S*)-4-hydroxyproline (hyp) **3**, affect the direction of ring pucker and also influence amide *cis*/*trans* conformational preferences.³ The two effects appear to be correlated.^{3a,4,8} In an effort to control the ring pucker variable and isolate the remaining effect of a substituent upon amide *cis*–*trans* preferences, we synthesized the 2-azabicyclo[2.1.1]hexanes **4**–**6** (Table 1),⁹ analogues of Pro **1**, flp **2**, and hyp **3**. *N*-Acetylmethanopyrrolidine methyl ester (MetPro) **4** displays a Pro **1** residue with *both* idealized C^γ-*exo* and C^γ-*endo* ring pucker. The substituted 4-*anti*-fluoromethanopyrrolidine (Metflp) **5** and 4-*anti*-hydroxymethanopyrrolidine (Methyp) **6**, when viewed from the perspective of the substituent-bearing bridges, are pyrrolidines (bolded bonds) with constrained C^γ-*exo* ring pucker. The relative substituent effects on *K*_{T/C} for these methanopyrrolines **4**–**6** was essentially invariant in D₂O, although in the less polar aprotic solvents CDCl₃ and 1,4-dioxane-*d*₈ Metflp **5** had a slightly larger *trans* preference than the others.

Received: January 17, 2011

Published: April 18, 2011

Table 1. $K_{T/C}$ of Methanoproline 4–6


compd	Y	$K_{T/C}^a$		
		D ₂ O	CDCl ₃	dioxane- <i>d</i> ₈
MetPro 4	H	3.5	2.4	2.2
MetFlp 5	F	3.5	2.7	2.8
Methyp 6	OH	3.6 ^b	2.4	2.1

^a Values of $K_{T/C}$ were measured at 25 °C using ¹⁹F NMR spectra for fluoro isomers and ¹³C NMR for MetPro 4 and Methyp 6 (see ref 9).
^b Values in ref 9 were measured in D₂O/CD₃OD ~ 4:1.





Figure 1. Amide equilibrium for a methanopyrrolidine 7.


Scheme 1. Retrosynthesis of Methanoproline 14–17 Related to Flp 8 and Hyp 9




This result was taken to indicate that the γ -substituent effect is primarily related to ring pucker and a resultant enhancement of the interaction between the amide carbonyl oxygen and ester carbonyl carbon.

Our previous study⁹ did not identify unresolved issues associated with using methanoproline 4–6 as mimics of proline 1–3. For example, it is not known if the carbonyl group of the amides in the mimics 4–6 has a structurally-related preference to be adjacent to the bridgehead H₁ or the methylene H₃ position. Knowledge of the amide preference of a methanopyrrolidine (Metpyr) 7 that is missing the α -ester adjacent to nitrogen (Figure 1) is necessary in order to determine the effect of a 3-ester substituent upon amide conformations.

Additionally, the scope of the methanoproline substituent effect study was limited to the MetFlp 5 and Methyp 6 stereoisomers related to flp 2 and hyp 3 by the synthetic approach available at that time. Thus, we were unable to address the generality of the finding for other methanoproline stereoisomers related to (2*S*,4*R*)-4-fluoroproline 8 (Flp) and the biologically relevant (2*S*,4*R*)-4-hydroxyproline (Hyp) 9 as to whether $K_{T/C}$ values are always independent of substituent and depend mainly on ring pucker. To answer these questions, a different synthetic approach is needed to prepare methanofluoroproline (MetFlps) 14 and 15, whose idealized C ^{γ} ring pucker contains either exo(*gauche*)- or endo(*anti*)-Flp 8 conformers, embedded in

Scheme 2. Synthetic Route to *N*-Protected 5-*syn*-Fluoromethanopyrrolidines

bold for emphasis in Scheme 1. The same is true for methanohydroxyproline (MetHyps) 16 and 17, related to Hyp 9. A possible synthetic approach to methanoproline could utilize as key synthons the methanopyrrolidines 10a–13a or related *O*-protected derivatives.





Herein, we describe 1,2-dihydropyridine-based syntheses of Metpyr 7 as well as *N*-acetyl-5-*syn*- and 5-*anti*-F(OH)-substituted methanopyrrolidines 10b–13b. The configurational preferences determined for these amides reveal that only small inherent trans/*cis* amide biases accompany the use of methanoproline as idealized C ^{γ} -puckered proline mimics. In a separate paper, we shall show how *N*-Boc-methanopyrrolidines 10a–13a, or related *O*-silylated derivatives, can serve as key synthons for a directed lithiation approach to the desired methanoproline derivatives 14–17.^{10,11}

RESULTS AND DISCUSSION

Metpyr 7 was prepared in 70% yield from *N*-Boc-methanopyrrolidine¹⁰ by removal of the Boc group with trifluoroacetic acid followed by acetylation with acetyl chloride.



Synthesis of 5-Fluoromethanopyrrolidines. *N*-Boc-5-*syn*-fluoro-Metpyr 10a was synthesized, as shown in Scheme 2, from pyridine-derived intermediate 18 that was prepared by a second-chance rearrangement route.¹² Conversion of fluoro alcohol 18 to the thionocarbonate 19 using *O*-phenyl chlorothionoformate¹³ followed by reductive deoxygenation afforded the *N*-benzyloxycarbonyl fluoride 20. Reductive removal of the protecting group using H₂/Pd(OH)₂ in methanol in the presence of (BOC)₂O afforded the *N*-BOC-5-*syn*-fluoro synthon 10a. The reduction of 20 in methanol followed by addition of acetyl chloride afforded the *N*-acetyl-5-*syn*-fluoroamide 10b.

In the 5-*anti*-fluoro series, *N*-Boc-5-*anti*-fluoro-methanopyrrolidine 11a was synthesized from 1,2-dihydropyridine photo-product 21 as shown in Scheme 3.^{14,15} Addition of BrF to 11a was accompanied by rearrangement to afford the 5-*anti*-bromo-

Scheme 3. Synthetic Route to *N*-Protected 5-*anti*-FluoromethanopyrrolidinesScheme 4. Synthetic Route to *N*-BOC-5-*syn*-*O*-TBS-methanopyrrolidine 28

6-*anti*-fluoro azabicyclo 22. Characteristic for the rearranged 2-azabicyclo[2.1.1]hexane structure for 22 was the ¹H NMR *W*-plan coupling between the bridgehead proton H₁ at δ 4.61 with H₄ at δ 3.20 (*J*_{1,4} = 7.2 Hz). Similarly, the 5-*anti*-6-*anti* stereochemistry for 22 was demonstrated by its *W*-plan coupling of proton H₅ at δ 4.18 with H₆ at δ 5.07 (*J*_{5,6} = 7.5 Hz), as well as their vanishingly small couplings to the flanking bridgehead protons H₁ and H₄.^{12,14} Bromo fluoride 22 was reductively debrominated to give 5-*anti*-fluoride 23. Reductive removal and reprotection, as described above for fluoride 20, afforded either the *N*-BOC-5-*anti*-fluoro synthon 11a¹⁶ or the *N*-acetyl fluoride 11b.

Synthesis of 5-Hydroxymethanopyrrolidines. For the 5-*syn*-hydroxy series, a silylated derivative of alcohol 12a, *N*-Boc-5-*syn*-OTBS-methanopyrrolidine 28, was synthesized from iodohydrin 24 as shown in Scheme 4.^{12,14} An inefficient, but necessary, mercuric bromide-mediated nucleophilic substitution reaction, during which nitrogen has migrated from C₁ to C₆, afforded the bromohydrin 25. The rearranged 2-azabicyclo[2.1.1]hexane structure of 25 was confirmed by the characteristic ¹H NMR *W*-plan coupling between bridgehead proton H₁ at δ 4.44 with H₄ at δ 2.92 (*J*_{1,4} = 6.8 Hz) and a geminal H₃ proton at δ 3.41 (*d*, *J*_{3,3'} = 11.3 Hz) that is not further coupled to H₄. The singlet at δ 3.57 identifies H₅ as *syn*, since there is no coupling with H₁ or H₄. Also, the absence of *W*-plan coupling between H₅ and H₆ at δ 4.77 identifies H₆ as *anti*. With the crucial 5-*syn*-alcohol in place, protection of the alcohol as the TBS ether 26

Scheme 5. Synthetic Route to *N*-Acetyl-5-*syn*-hydroxymethanopyrrolidinesScheme 6. Synthetic Route to *N*-Protected 5-*anti*-Hydroxymethanopyrrolidines

followed by reductive debromination gave the ether 27. Hydrogenolysis in the presence of (BOC)₂O gave *N*-BOC-5-*syn*-OTBS synthon 28.

N-Acetyl-5-*syn*-*O*-benzoate 29 and *N*-acetyl-5-*syn*-alcohol 12a were prepared from 25 as shown in Scheme 5. Benzylation of alcohol 25 gave a benzoate 29 that was reductively debrominated to afford benzoate 30. Hydrogenolysis and acetylation afforded the amide ester 31, which upon methanolysis afforded 5-*syn*-alcohol 12b.

For the 5-*anti*-hydroxy series, *N*-BOC-5-*anti*-alcohol 13a was prepared from bromoacetate 32,¹⁷ as shown in Scheme 6. Reductive debromination gave acetate 33. Methanolysis to 34 and then hydrogenolysis in the presence of (BOC)₂O gave *N*-BOC alcohol 13a. For investigation of *trans/cis* amide preferences, alcohol 13a was converted to the *N*-acyl benzoate¹⁸ 36, and this was converted by methanolysis to the alcohol 13b.

NMR Analysis of *K*_{T/C} for Substituted Methanopyrrolidines. A planar amide carbonyl in methanopyrrolidine 7 might be eclipsed with H₁ in a *cis* conformation or staggered between the two H₃ methylene protons in a *trans* orientation (Figure 2). Further, substituents might alter whatever inherent stereochemical preference might exist for 7. To resolve these issues, and to establish baseline amide conformational preferences for conformationally constrained methanopyrrolidines with heteroatom substituents, we determined *K*_{T/C} for the 5-*syn*- and 5-*anti*-fluoro-, hydroxy-, and benzyloxymethanopyrrolidines in Figure 2.

Amide trans/cis ratios shown in Table 2 were obtained by integration of nonoverlapping ^1H or ^{19}F NMR peaks. The percentages of trans isomers obtained by separate ^1H NMR integrations are reliable $\pm 1\%$. For an individual structure, isomer ratios can depend on the protons chosen to be integrated and compared and the percentage of trans isomer can vary from the average by $\pm 1.5\%$. ^{19}F and ^1H ratios ($K_{\text{T/C}}$) differ by no more than 0.1.

There is only a slight solvent dependence for methanopyrrolidine amide preferences of **7** and **10b–13b** (entries 1–5 Table 2). In polar protic D_2O , the 54% trans amide preference shown by MetPyr **7** is relatively unchanged ($\pm 1\%$) by either the syn or anti, fluoro or hydroxy, heteroatom substituents of **10b–13b**. In CDCl_3 solvent there is a bit more sensitivity to solvent (43–54% trans). The 5-*syn*-F **10b** and 5-*anti*-F isomers **11b** (entries 2 and 3) show essentially the same trans preferences in CDCl_3 within a few percent as the parent substrate **9** (entry 1), indicating that the dipolar C–F bond *does not* have a significant effect on amide preference for these methanopyrrolidine derivatives. With alcohol substitution, the 5-*syn*-OH **12b** (entry 4) in CDCl_3 has a clear cis amide preference, while the 5-*anti*-OH **15b** (entry 5) has little amide preference.

The $K_{\text{T/C}}$ results in Table 2 in apolar CDCl_3 solvent are in somewhat qualitative agreement with gas-phase relative energy calculations that generally favor small trans amide preferences. Only the 5-*syn*-OH **12b**, in agreement with experiment, is calculated to have a cis amide preference. An X-ray analysis of **12b** shows that there is no unusual distortion of the ring or internal hydrogen bonding interaction in the solid phase; the




Figure 2. Amide conformations for methanopyrrolidines.

Table 2. $K_{\text{trans/cis}}$ for *N*-Acetylmethanopyrrolidine Derivatives

entry	substrate	X	Y	$K_{\text{trans/cis}}$		dipole moment (μ)		$K_{\text{trans/cis}}$ calcd ^b
				D_2O^a	CDCl_3^a	trans	cis	
1	parent 7	H	H	1.2 (54:46)	1.1 (52:48)	4.34	4.30	1.2
2	<i>syn</i> -F 10b	F	H	1.1 (53:47)	0.9 (48:52) ^c	5.05	4.61	1.2
3	<i>anti</i> -F 11b	H	F	1.2 (55:45) ^d	1.2 (54:46) ^e	2.40	4.36	2.0
4	<i>syn</i> -OH 12b	OH	H	1.2 (54:46)	0.8 (43:57)	5.51	2.90	0.06
5	<i>anti</i> -OH 13b	H	OH	1.2 (54:46)	1.0 (51:49)	3.91	2.93	1.2
6	<i>syn</i> -OBz 31	OBz	H	1.4 (58:42)	1.8 (64:36)			
7	<i>anti</i> -OBz 36	H	OBz	1.3 (56:44)	1.6 (61:39)			

^a Ratios were obtained from ^1H NMR spectra. ^b MP2/6-31G(d,p)//RHF/6-31G(d) level. ^c $K_{\text{trans/cis}}$ 0.9 (46:54) by ^{19}F NMR. ^d $K_{\text{trans/cis}}$ = 1.3 (56:44) by ^{19}F NMR. ^e $K_{\text{trans/cis}}$ = 1.3 (57:43) by ^{19}F NMR.

amide nitrogen is nearly flat in both the cis and trans amide forms (see the Supporting Information).

Benzoylation of the alcohol groups results in little change in preference for trans amides in D_2O for both the 5-*syn*-OBz **31** (entry 6) and 5-*anti*-OBz **36** (entry 7) isomers. However, upon benzoylation the trans preference is enhanced in the less polar aprotic solvent CDCl_3 . Especially noteworthy is the switch from a cis amide preference for 5-*syn*-OH **12b** (entry 4) to a clear trans amide preference for the 5-*syn*-OBz **31**. In this constrained ring system a change in preferred ring pucker upon *O*-acylation can be ruled out as the cause of the enhancement effect.^{5b,f}

CONCLUSION

N-Acetylmethanopyrrolidine and its 5-*syn*/5-*anti*-F(OH) derivatives have been synthesized from pyridine via a 1,2-dihydropyridine photoproduct. The trans/cis amide preferences ($K_{\text{T/C}}$) for the parent **7** were compared with those of the stereoisomeric pairs of 5-*syn*(*gauche*)/*anti*-fluoro **10b/11b**, hydroxy **12b/13b**, and *O*-Bz isomers **31/36** in both D_2O and CDCl_3 solvent. The substituent effect differences ($K_{\text{T/C}}$ functionalized isomer – $K_{\text{T/C}}$ for **7**) were extremely small ($\Delta K_{\text{T/C}}$ = -0.3 to $+0.1$) for all cases studied, with the single minor exception of the OBz isomers in CDCl_3 ($\Delta K_{\text{T/C}}$ = 0.5 – 0.7). Further, in all of the pairs of stereoisomers studied the trans/cis amide preference was minimally influenced by the stereochemical orientation of the substituent ($K_{\text{T/C}}$ *syn*-isomer – $K_{\text{T/C}}$ *anti*-isomer = $\Delta K_{\text{T/C}}$ = -0.2 to $+0.3$).

The small trans amide preferences for methanopyrrolidine **7** in CDCl_3 or D_2O show that it is the interaction of the α -ester group and the amide of MetPro **4** that plays a major role in determining trans/cis ratios. Further, the small trans amide preferences for the substituted fluoro- and hydroxy-methanopyrrolidines is confirmation of previous work with the stereoisomers Metflp **5** and Methyp **6** that indicated the remote anti heteroatom has little additional effect upon trans amide preferences.⁹ The findings with rigid methanopyrrolidines are consistent with the proposal for prolines that substituent influences upon the pucker energetics of ring conformations, and the resulting impact upon the amide carbonyl and proline side-chain

carbonyl interaction, play the major role in determining trans/cis amide equilibria.^{3a,4,8}

For the four possible *N*-acetyl-5-fluoro- and -5-hydroxymethanopyrrolidines, we now have obtained $K_{T/C}$ values that establish baseline amide preferences in the absence of α -ester functionality. With this evidence, it will be possible to determine the contribution to trans amide preferences by α -ester substituents when other methanoproline are synthesized. The *N*-BOC-methanopyrrolidines **10b**, **11b**, **28**, and **13b** should prove useful in this endeavor to prepare fluoro- and hydroxymethanoproline **14–17**, constrained mimics of Flp and Hyp in idealized C' -exo and C' -endo conformations through which insights may be gained concerning amide preferences of prolines.

EXPERIMENTAL SECTION

General Methods. Thin-layer chromatography was performed on precoated plates of silica gel GF 250 μm . Column chromatography was performed on silica gel, Merck grade 60 (230–400 mesh). Reagent chemicals were obtained from commercial suppliers, and reagent grade solvents were used without further purification. The standard for ^1H NMR was CHCl_3 δ 7.26, for ^{13}C NMR CDCl_3 δ 77.0, and for ^{19}F NMR CFCl_3 δ 0.00; uncoupled ^{19}F spectra were referenced indirectly against a D-lock and required minor shift correction. Some NMR resonances appear as pairs because of carbamate conformations and italics denote minor rotamer peaks. Assignments of NMR resonances, where necessary, were facilitated by NOE, ^1H – ^1H -COSY, and HETCOR experiments. The trans/cis amide assignments were based upon observations of an NOE effect on either the characteristic bridgehead H_1 hydrogen or alternatively at the H_3 methylene hydrogen signals upon irradiation of the major or minor acetyl methyl singlets; italics denote minor rotamer peaks. Amide trans/cis ratios were obtained by integration of nonoverlapping ^1H or ^{19}F NMR peaks. Throughout this paper, we have chosen to use syn/anti nomenclature to identify the stereochemistry of substituents on the non-nitrogen containing bridges. This is to avoid the use of exo/endo nomenclature, confusing to those accustomed to naming related all-carbon-bridged bicyclic structures. The bridge with the nitrogen heteroatom is always the main bridge of highest priority. Thus, all substituents anti to nitrogen are endo.

***N*-Acetyl-2-azabicyclo[2.1.1]hexane (7).** To a solution of *N*-BOC-2-azabicyclo[2.1.1]hexane¹⁰ (42 mg, 0.229 mmol) in CH_2Cl_2 (5.0 mL) was added TFA (261 mg, 2.29 mmol) at rt under argon. After 6 h, the crude amine obtained upon workup was dissolved in CH_2Cl_2 (7.5 mL) to which DMAP (84 mg, 0.69 mmol) was added. The solution was cooled to 0 °C, and AcCl (54 mg, 0.69 mmol) was added to the reaction mixture. After being stirred for 3 h at room temperature, the reaction mixture was washed with water (2 \times 5 mL) and then the combined aqueous layer was backwashed with CH_2Cl_2 (4 mL). The organic layer was dried over Na_2SO_4 and filtered, and the solvent was removed in vacuo. Preparative TLC (1:9 MeOH/EtOAc) afforded 20 mg (70%) of **39** as a colorless oil at R_f = 0.39 (1:9 MeOH/ethyl acetate): ^1H NMR (400 MHz, D_2O) (italics denote minor rotamer peaks) δ 4.64 (dt, J = 6.9, 1.8 Hz, 1H, H_1), 4.46 (dt, J = 6.9, 1.8 Hz, 1H, H_1), 3.54 (s, 2H, H_3), 3.36 (s, 2H, H_3), 2.93 (m, 1H, H_4), 2.11 (s, 3H, COCH_3), 2.07 (s, 3H, COCH_3), 2.07 (m, 2H, H_{Santi}), 2.04 (m, 2H, H_{Santi}), 1.44 (m, 2H, H_{Syn}), 1.37 (m, 2H, H_{Syn}); NOE (D_2O) the major H_1 signal at δ 4.46 on irradiation sees the acetyl signal at δ 2.11 and the minor H_1 signal at δ 4.64 sees no acetyl signal. The minor H_3 signal at δ 3.54 on irradiation enhances the acetyl signal at δ 2.07 and the major H_3 signal at δ 3.36 on irradiation enhances no acetyl signal. $K_{\text{trans/cis}}$ = 52/48 (CDCl_3) based upon H_1 integrations; the major upfield H_1 is trans. $K_{\text{trans/cis}}$ = 54/46 (D_2O) based upon H_1 integrations.

***N*-Acetyl-2-azabicyclo[2.1.1]hexane (9):** ^1H NMR (400 MHz, CDCl_3) (italics denote minor rotamer peaks) δ 4.78 (dt, J = 6.9, 1.8 Hz, 1H, H_1), 4.25 (dt, J = 6.9, 1.8 Hz, 1H, H_1), 3.39 (s, 2H, H_3), 3.38 (s, 2H, H_3), 2.89 (m, 1H, H_4), 2.06 (s, 3H, COCH_3), 2.01 (s, 3H, COCH_3), 1.98 (m, 2H, H_{Santi}), 1.93 (m, 2H, H_{Santi}), 1.43 (m, 2H, H_{Syn}), 1.33 (m, 2H, H_{Syn}); ^{13}C NMR (400 MHz, CDCl_3) δ 168.6 and 168.0, 62.5 and 59.1, 50.1 and 48.3, 41.1 and 40.2, 38.7 and 37.9, 21.6 and 21.5; HRMS m/z found 125.0834, calcd for $\text{C}_7\text{H}_{11}\text{NO}$ (M) 125.0836.

***N*-(Benzyloxycarbonyl)-5-syn-fluoro-6-anti-(phenoxy-carbonothioxyloxy)-2-azabicyclo[2.1.1]hexane (19).** To 5-syn-fluoro-6-anti-hydroxy-2-azabicyclo[2.1.1]hexane¹² **18** (170 mg, 0.68 mmol) in CH_2Cl_2 (15 mL) were added pyridine (219 μL , 2.7 mmol) and a catalytic amount of DMAP. To the resulting solution was added *O*-phenyl chlorothionoformate (111 μL , 1.02 mmol) carefully under argon at rt.¹³ After 2 h, the reaction mixture was quenched with satd NH_4Cl (aq) (5 mL) and diluted with CH_2Cl_2 (10 mL). The aqueous layer was extracted with CH_2Cl_2 (3 \times 15 mL), and all of the CH_2Cl_2 layers were combined and dried using Na_2SO_4 . Removal of the solvent in vacuo followed by silica gel flash chromatography gave 230 mg (88%) of **19** at R_f = 0.60 (1:1 hexane/diethyl ether): ^1H NMR (400 MHz, CDCl_3) δ 7.37–7.01, 5.12 (dd, J = 56.4, 6.8 Hz, 1H, H_5), 5.11 (s, 2H), 4.86 (d, J = 20.8 Hz, 1H, H_6), 4.78 (dd, J = 21.1, 6.8 Hz, 1H, H_1), 3.61 (two d, J = 9.0 Hz, 1H, H_3), 3.45 (d, J = 9.0 Hz, 1H, H_3), 3.27 (br, 1H, H_4); ^{13}C NMR (100 MHz) δ 194.1 (C=S), 157.9, 156.3 (C=O), 153.5, 136.69, 130.1, 128.9, 128.6, 128.5, 128.3, 127.3, 122.0, 85.9, 83.5, 78.9, 78.7, 67.7, 64.6, 64.4, 47.3, 47.1, 44.3, 44.3; HRMS m/z 388.1019, calcd for $\text{C}_{20}\text{H}_{19}\text{FNO}_4\text{S}$ (M + H), m/z 388.1014, calcd for 410.0844 $\text{C}_{20}\text{H}_{18}\text{FNaNO}_4\text{S}$ (M + Na) 410.0833.

***N*-(Benzyloxycarbonyl)-5-syn-fluoro-2-azabicyclo[2.1.1]hexane (20).** Compound **19** (129 mg, 0.33 mmol) was dissolved in dry toluene (8.3 mL) and degassed for 1 h with Ar. Separately, AIBN (8.2 mg, 0.05 mmol) and $(\text{TMS})_3\text{SiH}$ (100 mg, 0.5 mmol) were dissolved in dry toluene (13.7 mL) and degassed for 1 h with Ar. The flask was then lowered into a 90 °C oil bath, and the AIBN/ $(\text{TMS})_3\text{SiH}$ solution was added slowly via canula. The reaction was monitored by TLC for disappearance of starting material at R_f = 0.6 (1:1 hexane/ether). After 22 h, a second portion of AIBN/TTMSS dissolved in dry toluene degassed for 1 h with Ar was added to the flask. After 3 h, TLC showed no remaining starting material. Solvent was removed in vacuo resulting in a pale yellow oil. The crude material after preparative TLC at R_f = 0.3 (1:1 hexane/ether) yielded 53 mg (71%) of **20**: ^1H NMR (400 MHz, CDCl_3) δ 7.16 (m, 5H), 5.02 (s, 2H), 4.36 (br, 1H, H_1), 4.27 (d, J = 58.8 Hz, 1H, H_5), 3.37, 3.35 (two d, J = 8.0, 7.6 Hz, 1H, H_3), 3.19, 3.17 (two d, J = 7.6, 7.6 Hz, 1H, H_3), 2.77 (br, 1H, H_4), 1.12 (dd, J = 37.2, 5.9 Hz, 1H, H_6), 1.14 (s, H_6); ^{13}C NMR (100 MHz, CDCl_3) δ 157.3, 137.2, 129.0, 128.8, 128.6, 128.4, 128.3, 128.2, 85.0, 84.9, 82.7, 82.7, 67.2, 62.6, 62.5, 62.2, 62.1, 45.3, 42.4, 42.2, 42.0, 29.9, 26.7, 26.6, 26.4; HRMS m/z 258.0898, calcd for $\text{C}_{13}\text{H}_{14}\text{FNO}_2\text{Na}$ (M + Na) 258.0901.

***N*-(tert-Butoxycarbonyl)-5-syn-fluoro-2-azabicyclo[2.1.1]hexane (10a). General Procedure for *N*-COOBn to *N*-BOC Conversion.** To a solution of **20** (190 mg, 0.81 mmol) in MeOH (10 mL) was added $\text{Pd}(\text{OH})_2$ (56 mg, 10 mol %) followed by $(\text{BOC})_2\text{O}$ (231 mg, 1.1 mmol). The resulting solution was stirred at rt for 2 h under hydrogen. Filtration of the catalyst followed by silica gel flash chromatography gave 80 mg (50%) of the fluoride **10a** at R_f = 0.45 (1:1 hexane/diethyl ether): ^1H NMR (500 MHz, CDCl_3) δ 4.46 (br, 1H, H_1), 4.41 (d, J = 58.8 Hz, 1H, H_5), 3.41 (dd, J = 23.5, 7.5 Hz, 1H, H_{3n}), 3.24 (br, 1H, H_{3x}), 2.88 (br, 1H, H_4), 1.46 (s, 9H), 1.29 (m, 2H, 2H_6); ^{13}C NMR (100 MHz, CDCl_3) δ 157.2, 85.2, 82.8, 79.9, 62.8, 62.6, 61.7, 61.6, 45.5, 44.9, 42.3, 42.1, 29.0, 28.8, 28.6, 28.4, 26.8, 26.6, 26.4; HRMS m/z 224.1072, calcd for $\text{C}_{10}\text{H}_{16}\text{FNO}_2\text{Na}$ (M + Na) 224.1063.

***N*-Acetyl-5-syn-fluoro-2-azabicyclo[2.1.1]hexane (10b). General Procedure for Acetylation.** Carbamate **20** (56 mg, 0.24 mmol) and 10% Pd/C (13 mg, 0.012 mmol) were placed under Ar and suspended in dry THF (5.6 mL). The vessel was repeatedly evacuated and placed

under H₂ six times. H₂ was bubbled through the suspension for 15 min followed by capping with a H₂-filled balloon (2 L). Acetic anhydride (0.025 mL, 0.26 mmol) and TEA (0.033 mL, 0.024 mmol) freshly distilled from CaH₂ were added via syringe. After being stirred for 3 h, the Pd/C was filtered through a Celite plug, and the solvent was removed in vacuo. The crude oil purified by silica gel flash chromatography at R_f = 0.14 (1% MeOH in DCM) gave 19.5 mg (59%) of amide **10b**: ¹H NMR (500 MHz, CDCl₃) δ 4.88 (dm, *J* = 6.9 Hz, 1H, major H₁), 4.49 (ddd, *J* = 58.4, 2.8, 2.3 Hz, 1H, minor H₅), 4.46 (ddd, *J* = 58.3, 2.9, 2.0 Hz, 1H, major H₅), 4.33 (dddd, *J* = 6.4, 1.8, 1.74, 1.74 Hz, 1H, minor H₁), 3.54 (d, *J* = 9.7 Hz, 1H, minor H₃), 3.50 (d, *J* = 8.0 Hz, 1H, major H₃), 3.37 (overlapping d, 2H, H₃), 2.98 (m, 1H, H₄), 2.07 (two s, 6H, COCH₃). 1.45–1.23 (m, 2H, H₆); ¹³C NMR (100 MHz, CDCl₃) δ 170.2, 169.7, 83.8 (d, *J* = 241.1 Hz), 83.2 (d, *J* = 240.8 Hz), 63.86 (d, *J* = 17.4 Hz), 60.67 (d, *J* = 17.0 Hz), 45.91 (d, *J* = 3.3 Hz), 44.29 (d, *J* = 2.8 Hz), 42.42 (d, *J* = 18.4 Hz), 41.75 (d, *J* = 18.6 Hz), 27.43 (d, *J* = 17.6 Hz), 26.26 (d, *J* = 18.0 Hz), 22.10, 21.70; ¹H NMR (500 MHz, D₂O) δ 4.72 (1H, minor H₁), 4.67 (ddd, *J* = 58.9, 3.1, 2.0, 1H, H₅), 4.65 (major coupling from HSQC *J* = 59 Hz, 1H, H₅), 4.56 (dq, *J* = 6.3, 1.82 Hz, 1H, major H₁), 3.56 (dt, *J* = 8.7, 1.1 Hz, 1H, minor H₃), 3.53 (dd, *J* = 8.7, 0.7 Hz, 1H, minor H₃), 3.41 (d br, *J* = 9.7 Hz, 1H, major H₃), 3.34 (d, *J* = 9.7 Hz, 1H, major H₃), 3.08–3.04 (m, 1H, H₄), 3.04–3.01 (m, 1H, H₄), 2.1 (s, 3H, major COCH₃), 2.09 (s, 3H, minor COCH₃), 1.47 (dm, *J* = 9.3 Hz, 1H, H_{6eq}), 1.42 (dm, *J* = 9.3 Hz, 1H, H_{6eq}), 1.42 (dd, *J* = 9.3 Hz, 1H, H_{6ax}), 1.34 (dd, *J* = 9.3 Hz, 1H, H_{6ax}); ¹⁹F NMR (376 MHz, CDCl₃) δ –177.2 and –177.6 (ratio 1:1.16); ¹⁹F NMR (376 MHz, D₂O) δ –176.9 (br, overlapping conformers); ¹H NMR NOE (CDCl₃) pulse δ 4.33 ppm (minor H₁) hits δ 2.09, 4.57, 1.38. Pulse δ 4.88 (major H₁) hits δ 4.46 (H₅ major), 1.33; NOE (D₂O) pulse δ 1.97 hits δ 3.55 and 4.57. and pulse δ 2.04 hits δ 4.57 only; *K*_{trans/cis} = 48/52 (CDCl₃) and 53/47 (D₂O) based upon H₁ integrations or *K*_{trans/cis} = 46/54 (CDCl₃) based upon ¹⁹F integrations; HRMS *m/z* 144.0823, calcd for C₇H₁₀FNO (M + H) 144.0819.

N-(Benzyloxycarbonyl)-5-anti-bromo-6-anti-fluoro-2-azabicyclo[2.1.1]hexane (22). To a solution of alkene¹⁴ **21** (398 mg, 1.85 mmol) in CH₃NO₂ (15 mL) was added NBS (461 mg, 2.6 mmol) at 0 °C followed by Et₃N·3HF (753 μL, 4.62 mmol) dropwise over a period of 10 min.¹⁵ The reaction mixture was brought to rt and stirred for 16 h, after which it was diluted with CH₂Cl₂ (40 mL), washed with NaHCO₃ (15 mL) and brine (15 mL), and dried over Na₂SO₄ to give 876 mg of a crude oil. Silica gel flash column chromatography gave 150 mg of the unreacted olefin **21** (37%) and 212 mg (38%) of **22** at R_f = 0.45 (1:1 hexane/ether); ¹H NMR (400 MHz, CDCl₃) δ 7.43 (m, 5H), 5.22 (s, 2H), 5.07 (dd, *J* = 59.4, 7.5 Hz, H₆), 4.61 (d, *J* = 7.2 Hz, 1H, H₁), 4.18 (dd, *J* = 7.5, 3.0 Hz, H₅), 3.68 (dd, *J* = 12.0, 1.8 Hz, H₃), 3.58 (d, *J* = 12.0 Hz, H₃), 3.20 (br, 1H, H₄); ¹³C NMR (100 MHz, CDCl₃) δ 155.5, 136.8, 128.8, 128.3, 128.2, 100.2 (*J* = 224 Hz), 65.1, 64.8, 50.3, 49.6, 48.5; HRMS *m/z* found 336.0014, calcd for C₁₃H₁₃NO₂FNaBr⁷⁹ (M + Na) 336.0011.

N-(Benzyloxycarbonyl)-5-anti-fluoro-2-azabicyclo[2.1.1]-hexane (23). **General Procedure for Reductive Debromination.** To a solution of **22** (222 mg, 0.71 mmol) in benzene (25 mL) were added *n*-Bu₃SnH (263 μL, 0.98 mmol) and AIBN (21 mg). The resulting solution was refluxed for 16 h. Solvent was removed in vacuo, and the crude was chromatographed to give 130 mg (78%) of **23** at R_f = 0.39 (1:1 hexane/ether): ¹H NMR (400 MHz, CDCl₃) δ 7.34 (m, 5H), 5.15 (s, 2H), 4.80 (dd, *J* = 62.1, 7.2 Hz, H₅), 4.41 (brd, *J* = 6.0 Hz, 1H, H₁), 3.45 (s, 2H, 2H₃), 2.86 (brm, 2H, H₄ and H_{6ax}), 1.74 (ddd, *J* = 7.8, 7.7, 2.6 Hz, H_{6n}); ¹³C NMR (100 MHz, CDCl₃) δ 157.3, 136.3, 128.8, 128.3, 128.2, 98.4 (d, *J*_{CF} = 209 Hz), 66.9 and 66.8, 62.0, 47.3, 43.4 and 43.1, 36.7; HRMS *m/z* found 258.0907, calcd for C₁₃H₁₄NO₂FNa (M + Na) 258.0907.

N-(tert-Butoxycarbonyl)-5-anti-fluoro-2-azabicyclo[2.1.1]-hexane (11a)¹⁶. According to the general procedure for **10a**, to carbamate **23** (42 mg, 0.18 mmol) in MeOH (10 mL) was added

Pd(OH)₂ (15 mg) followed by (BOC)₂O (47 mg, 2.15 mmol). After the mixture was stirred at rt for 2 h under hydrogen there was obtained 25 mg (71%) of **11a**: R_f = 0.39 (1:1 hexane/ether); ¹H NMR (400 MHz, CDCl₃) δ 4.80 (dd, *J* = 62, 7.9 Hz, H₅), 4.30 (br, H₁), 3.36 (q, *J* = 9.7 Hz, 2H₃), 2.83 (m, 2H, H₄ and H_{6ax}), 1.70 (ddd, *J* = 7.9, 7.3, 2.7 Hz, H_{6n}), 1.45 (s, 9H, BOC); ¹³C NMR (100 MHz, CDCl₃) δ 155.4, 98.6 (d, *J*_{CF} = 210 Hz, C₅), 79.9, 62.2, 47.2, 43.4 and 43.2, 36.7, 28.4; HRMS *m/z* found 224.1052, calcd for C₁₀H₁₆FNO₂ [M + Na] 224.1063.

N-(Acetyl)-5-anti-fluoro-2-azabicyclo[2.1.1]hexane (11b). According to the general procedure, carbamate **23** (96 mg, 0.41 mmol) and 10% Pd/C (22 mg, 0.02 mmol) were placed under Ar and suspended in dry THF (5.6 mL). Hydrogenation, followed by addition of acetic anhydride (0.042 mL, 0.45 mmol) and TEA (0.056 mL, 0.41 mmol), and workup afforded 14 mg (24%) of amide **11b**: R_f = 0.16 (1% MeOH in DCM); ¹H NMR (500 MHz, CDCl₃) δ 4.82 (dd, *J* = 62.4, 7.2 Hz, 1H, H₅ major), 4.78 (dd, *J* = 62.2, 7.3 Hz, 1H, H₅ minor) 4.77 (1H, H₁, minor) 4.26 (d, *J* = 6.7 Hz, 1H, H₁ major), 3.49 (m, 2H, H₃), 2.91 (m, 2H, H₄, H₆) 1.78 (td, *J* = 7.8, 2.4 Hz, 1H, H_{6ax}) 1.71 (td, *J* = 7.8, 2.4 Hz, 1H, H_{6y}); ¹³C NMR (75 MHz, CDCl₃) δ 169.17, 168.72, 98.51 (d, *J* = 214.2 Hz), 98.43 (d, *J* = 213.3 Hz), 64.13 (d, *J* = 21.8 Hz), 60.76 (d, *J* = 21.9 Hz), 48.62 (d, *J* = 5.1 Hz), 46.79 (d, *J* = 4.9 Hz), 43.79 (d, *J* = 18.4 Hz), 43.15 (d, *J* = 17.8 Hz), 37.70, 36.70; HRMS *m/z* 144.0823, calcd for C₇H₁₀FNO (M + H) 144.0819. ¹⁹F NMR (376 MHz, CDCl₃) δ –206.1 and –206.8 (ratio = 1.3:1.0); ¹⁹F NMR (376 MHz, D₂O) δ –205.2 and –206.8 (ratio = 1.0:0.79); ¹H NMR (500 MHz, D₂O) δ 4.89 (dd, *J* = 62.1, 7.3 Hz, 1H, H₅ major), 4.87 (dd, *J* = 62.2, 7.3 Hz, 1H, H₁ minor), 4.62 (ddd, *J* = 7.4, 1.9, 1.1 Hz, 1H, H₁ minor), 4.48 (ddd, *J* = 7.1, 1.9, 1.0 Hz, 1H, H₁ major), 3.62 (m, 1H, H_{3,3'}, minor), 3.45 (dd, *J* = 10.0, 3.5 Hz, 1H, H₃, major), 3.41 (d, *J* = 10.2 Hz, 1H, H₃, major), 2.97 (m, 1H, H₄), 2.89 (m, 1H, H_{6anti}), 2.08 (s, 3H), 2.03 (s, 3H), 1.80 (ddd, *J* = 8.5, 7.3, 2.7 Hz, 1H, H_{6syn} major), 1.74 (ddd, *J* = 8.5, 7.3, 2.7 Hz, 1H, H_{6syn} minor); NOE (D₂O) pulse δ 2.03 hits δ 3.62 (H₃ minor); pulse δ 2.08 (pulls 2.03 into pulse) hits δ 3.62, 4.47 (H₁ major). NOE (CDCl₃): pulse δ 2.02 hits δ 3.48; pulse δ 2.06 (pulls 2.02 into pulse) hits δ 4.25 (major H₁), δ 3.48; *K*_{trans/cis} = 54/46 (CDCl₃) and *K*_{trans/cis} = 55/45 (D₂O) based upon H₁ integrations or *K*_{trans/cis} = 57/43 (CDCl₃) and 56:44 (D₂O) based upon ¹⁹F integrations.

N-(Benzyloxycarbonyl)-5-anti-bromo-6-syn-hydroxy-2-azabicyclo[2.1.1]hexane (25). To a stirred solution of iodohydrin **24** (1000 mg, 2.784 mmol) in MeNO₂ (100 mL) was added mercuric bromide (2509 mg, 6.961 mmol, 2.5 equiv).^{12,14} The solution was heated at 65 °C for 15 h. The mixture was diluted with brine (50 mL) and extracted with ether (4 × 150 mL). The ether extracts were combined, washed with brine (2 × 100 mL), dried over MgSO₄, evaporated under reduced pressure, and chromatographed (gradient: 25–40% ether in hexanes) to afford 269 mg (31%) of rearranged bromohydrin **25** as a colorless oil: R_f = 0.44 (2:3 ethyl acetate/hexanes) (unreacted HgBr₂ is UV active and NMR blind, and separation was difficult); ¹H NMR (400 MHz, CDCl₃) δ 7.39–7.29 (m, 5H), 5.15 (br, 2H), 4.77 (br, 1H, H₆), 4.44 (dd, *J* = 6.8, 1.7 Hz, 1H, H₁), 4.41 (dd, *J* = 6.8, 1.7 Hz, 1H, H₁), 3.57 (s, 1H, H₅), 3.58–3.51 (m, 3H, 2H₃ and H₅), 3.41 (d, *J* = 11.3 Hz, 1H, H₃), 3.36 (d, *J* = 11.9 Hz, 1H, H₃), 3.13 (br, 1H, OH), 2.92 (m, 1H, H₄), 2.87 (m, 1H, H₄); ¹³C NMR (100 MHz, CDCl₃) δ 156.8, 136.3, 128.5, 128.1, 127.9, 71.4 and 70.2, 67.4 and 67.3, 49.9 and 49.7, 45.5, 43.1, 14.7; HRMS *m/z* found 334.0045, calcd for C₁₃H₁₄BrNO₃Na (M + Na) 334.0049.

N-(Benzyloxycarbonyl)-5-anti-bromo-6-syn-(tert-butylidimethylsilyloxy)-2-azabicyclo[2.1.1]hexane (26). To a solution of bromohydrin **25** (257 mg, 0.823 mmol) in dry CH₂Cl₂ (10 mL) under argon was added imidazole (280 mg, 4.116 mmol, 5.0 equiv) followed by TBSCl (149 mg, 0.988 mmol, 1.2 equiv) in small portions. The resulting solution was stirred at rt for 6 h. The solvent was removed in vacuo and then chromatographed (10% ethyl acetate in hexanes) on silica gel to give 312 mg (89%) of bromo-*O*-silyl ether **26** as a colorless oil: R_f = 0.44 (1:5 ethyl acetate/hexanes); ¹H NMR (400 MHz, CDCl₃) δ 7.39–7.27

(m, 5H), 5.21–5.00 (m, 2H), 4.67 (*br s*, 1H, H_6), 4.65 (*br s*, 1H, H_6), 4.44 (*dd*, $J = 6.9, 1.4$ Hz, 1H, H_1), 4.38 (*dd*, $J = 6.9, 1.4$ Hz, 1H, H_1), 3.58 (*s*, 1H, H_5), 3.57–3.28 (m, 2H, 2 H_3), 2.91–2.79 (m, 1H, H_4), 0.91–0.78 (m, 9H), 0.09–0.01 (m, 6H); ^{13}C NMR (100 MHz, CDCl_3) δ 156.7 and 156.1, 136.6 and 136.4, 128.4, 128.1, 128.0, 127.9, 127.8, 70.4 and 70.3, 68.0 and 67.6, 67.0 and 66.8, 50.4 and 50.3, 45.7 and 45.6, 43.2 and 43.0, 25.5, 17.8, –5.1 and –5.2; HRMS m/z found 448.0923, calcd for $\text{C}_{19}\text{H}_{28}\text{BrNO}_3\text{SiNa}$ ($M + \text{Na}$) 448.0914.

***N*-(Benzyloxycarbonyl)-5-syn-(*tert*-butyldimethylsilyloxy)-2-azabicyclo[2.1.1]hexane (27).** According to the general reductive procedure for **23**, to a solution of bromo-*O*-silyl ether **26** (304 mg, 0.713 mmol) in dry toluene (20 mL) were added $(\text{TMS})_3\text{SiH}$ (440 μL , 1.426 mmol, 2.0 equiv) and AIBN (30 mg). After 2 h at 70 °C, workup and flash chromatography (1:9 ethyl acetate/hexanes) gave 183 mg (74%) of *O*-silyl ether **27** as a colorless oil: $R_f = 0.41$ (1:6 ethyl acetate/hexanes); ^1H NMR (400 MHz, CDCl_3) δ 7.41–7.22 (m, 5H), 5.21–5.01 (m, 2H), 4.29 (*dt*, $J = 6.7, 1.5$ Hz, 1H, H_1), 4.23 (*dt*, $J = 6.7, 1.5$ Hz, 1H, H_1), 3.69 (m, 1H, H_5), 3.47 (*d*, $J = 8.4$ Hz, 1H, H_3), 3.45 (*d*, $J = 8.4$ Hz, 1H, H_3), 3.22 (*d*, $J = 8.4$ Hz, 1H, H_3'), 3.19 (*d*, $J = 8.3$ Hz, 1H, H_3'), 2.64 (m, 1H, H_4), 1.28 (m, 1H, $H_{6\text{anti}}$), 1.26 (m, 1H, $H_{6\text{anti}}$), 1.20 (*d*, $J = 8.1$ Hz, 1H, $H_{6\text{syn}}$), 1.17 (*d*, $J = 8.1$ Hz, 1H, $H_{6\text{syn}}$), 0.84 (*s*, 9H), 0.04 (*s*, 6H), 0.03 (*s*, 6H); ^{13}C NMR (100 MHz, CDCl_3) δ 157.4 and 156.9, 137.2 and 137.0, 128.3, 127.9, 127.7, 69.6 and 69.5, 66.5 and 66.4, 63.7 and 63.4, 45.3 and 45.2, 42.8 and 42.7, 28.6 and 28.2, 25.6, 17.8, –5.1 and –5.2; HRMS m/z found 348.1994, calcd for $\text{C}_{19}\text{H}_{30}\text{NO}_3\text{Si}$ ($M + \text{H}$) 348.1989.

***N*-(*tert*-Butoxycarbonyl)-5-syn-(*tert*-butyldimethylsilyloxy)-2-azabicyclo[2.1.1]hexane (28).** To a solution of *O*-silyl ether **27** (231 mg, 0.665 mmol) in MeOH (10 mL) was added $\text{Pd}(\text{OH})_2$ (50 mg) followed by $(\text{BOC})_2\text{O}$ (174 mg, 0.798 mmol, 1.2 equiv). After 3 h under hydrogen at rt, workup and silica gel chromatography gave 184 mg (88%) of carbamate **28** as a colorless oil: $R_f = 0.52$ (1:6 ethyl acetate/hexanes); ^1H NMR (400 MHz, CDCl_3) δ 4.21 (*dt*, $J = 6.8, 1.6$ Hz, 1H, H_1), 4.11 (*dt*, $J = 6.8, 1.6$ Hz, 1H, H_1), 3.65 (m, 1H, H_5), 3.36 (*d*, $J = 8.3$ Hz, 1H, H_3), 3.31 (*d*, $J = 8.3$ Hz, 1H, H_3), 3.13 (*d*, $J = 8.3$ Hz, 1H, H_3'), 3.09 (*d*, $J = 8.3$ Hz, 1H, H_3'), 2.60 (m, 1H, H_4), 1.45 (*s*, 9H, Boc), 1.44 (*s*, 9H, Boc), 1.23 (m, 1H, $H_{6\text{anti}}$), 1.21 (m, 1H, $H_{6\text{anti}}$), 1.56 (*d*, $J = 8.9$ Hz, 1H, $H_{6\text{syn}}$), 1.13 (*d*, $J = 8.9$ Hz, 1H, $H_{6\text{syn}}$), 0.86 (*s*, 9H, TBS), 0.04 (*s*, 6H, TBS); ^{13}C NMR (100 MHz, CDCl_3) δ 156.7 and 156.4, 78.8, 69.6, 63.8 and 62.7, 45.2 and 44.6, 42.8, 28.7, 28.5, 25.7, 17.9, –5.0; HRMS m/z found 314.2154, calcd for $\text{C}_{16}\text{H}_{22}\text{NO}_3\text{Si}$ ($M + \text{H}$) 314.2146.

***N*-(Benzyloxycarbonyl)-5-anti-bromo-6-syn-benzoyloxy-2-azabicyclo[2.1.1]hexane (29).** Bromohydrin **25** (51 mg, 0.163 mmol) was dissolved in dry CH_2Cl_2 (2.5 mL). The solution was cooled to 0 °C and treated sequentially with triethylamine (115 μL , 0.817 mmol), DMAP (22 mg, 0.180 mmol), and benzoyl chloride (40 μL , 0.327 mmol).¹⁸ The reaction mixture was stirred for 30 min at 0 °C, allowed to come to room temperature, and then stirred for 3 h. The reaction mixture was quenched with water (2 \times 1 mL) and extracted with CH_2Cl_2 (2 \times 0.5 mL). The combined organic layers were dried and evaporated to dryness. The residue was purified by chromatography on silica gel (prep TLC: 1:4 ethyl acetate/hexanes) to afford 59 mg (87%) bromobenzoate ester **29** as a light orange oil at $R_f = 0.33$ (4:1 hexanes/ethyl acetate); ^1H NMR (400 MHz, CDCl_3) δ 8.10–7.17 (m, 10H), 5.70 (*br s*, 1H, H_6 and its rotamer), 5.09 (m, 2H), 4.80 (*d*, $J = 6.6$ Hz, 1H, H_1), 4.74 (*d*, $J = 6.6$ Hz, 1H, H_1), 3.78 (*s*, 1H, H_5), 3.69–3.47 (m, 3H, 2 H_3 and H_3 rotamer), 3.28 (*dd*, $J = 6.6, 2.7$ Hz, 1H, H_4), 3.23 (*dd*, $J = 6.6, 2.7$ Hz, 1H, H_4); ^{13}C NMR (100 MHz, CDCl_3) δ 165.0, 156.7, 136.0, 133.5, 129.6, 128.9, 128.5, 128.4, 128.1, 127.8, 72.0 and 70.9, 67.3 and 67.1, 66.9 and 66.3, 49.5 and 49.2, 46.0, 43.5 and 43.2; HRMS m/z found 416.0510, calcd for $\text{C}_{20}\text{H}_{19}\text{BrNO}_4$ ($M + \text{H}$) 416.0492.

***N*-(Benzyloxycarbonyl)-5-syn-benzoyloxy-2-azabicyclo[2.1.1]hexane (30).** According to the general procedure, to a solution of bromobenzoate ester **29** (223 mg, 0.536 mmol) in dry toluene (15 mL)

were added Bu_3SnH (285 μL , 1.072 mmol) and AIBN (9 mg). After 3 h at 70 °C, workup and flash chromatography (1:5 ethyl acetate/hexanes) gave 130 mg (72%) of benzoate ester **30** as a light orange oil: $R_f = 0.34$ (1:3 ethyl acetate/hexanes); ^1H NMR (400 MHz, CDCl_3) δ 7.96–7.20 (m, 10H), 5.08 (*d*, $J = 12.4$ Hz, 1H), 5.02 (*d*, $J = 12.3$ Hz, 1H), 4.8 (m, 1H, H_5 and its conformer), 4.67 (*brd*, $J = 6.6$ Hz, 1H, H_1), 4.61 (*brd*, $J = 6.6$ Hz, 1H, H_1), 3.59 (*d*, $J = 9.1$ Hz, 1H, H_3), 3.50 (*d*, $J = 9.1$ Hz, 1H, H_3), 3.40 (*d*, $J = 9.1$ Hz, 1H, H_3'), 3.37 (*d*, $J = 9.1$ Hz, 1H, H_3'), 3.07 (m, 1H, H_4), 1.64 (m, 1H, $H_{6\text{anti}}$ and its conformer), 1.47 (m, 1H, $H_{6\text{syn}}$ and its conformer); ^{13}C NMR (100 MHz, CDCl_3) δ 165.4 and 165.3, 157.5 and 156.8, 136.8 and 136.6, 133.3, 129.6, 128.5, 128.3, 127.8, 127.7, 69.4, 66.8 and 66.7, 62.6 and 62.0, 45.9 and 45.6, 42.0 and 41.6, 30.1 and 29.8; HRMS m/z found 338.1386, calcd for $\text{C}_{20}\text{H}_{20}\text{NO}_4$ ($M + \text{H}$) 338.1387.

***N*-Acetyl-5-syn-benzoyloxy-2-azabicyclo[2.1.1]hexane (31).** According to the general procedure, to a solution of benzoate ester **30** (102 mg, 0.302 mmol) in MeOH (2 mL) was added $\text{Pd}(\text{OH})_2$ (30 mg). After 3 h under hydrogen at RT workup gave a crude amine that was dissolved in dry CH_2Cl_2 (10 mL) and cooled to 0 °C. DMAP (110 mg, 0.907 mmol, 3 equiv) and AcCl (65 μL , 0.907 mmol, 3 equiv) was added to the reaction mixture maintained for 30 min at 0 °C and then brought to RT. After 3 h at RT workup and chromatography (1:4 hexanes/ethyl acetate) afforded 45 mg (61%) of **31** as a light orange oil at $R_f = 0.24$ (ethyl acetate); ^1H NMR (400 MHz, CDCl_3) δ 7.93 (m, 2H), 7.54 (m, 1H), 7.40 (m, 2H), 4.98 (*dt*, $J = 6.8, 1.8$ Hz, 1H, H_1), 4.75 (*dd*, $J = 3.0, 1.9$ Hz, 1H, H_5), 4.72 (*dd*, $J = 3.0, 1.9$ Hz, 1H, H_5), 4.50 (*dt*, $J = 6.4, 1.8$ Hz, 1H, H_1), 3.60 (*brd*, $J = 9.7$ Hz, 1H, H_3), 3.40 (m, 1H, H_3 conformer and 1H, H_3' and its conformer), 3.15 (m, 1H, H_4), 3.08 (m, 1H, H_4), 2.05 (*s*, 3H, Ac), 2.00 (*s*, 3H, Ac), 1.69 (m, 1H, $H_{6\text{anti}}$), 1.63 (m, 1H, $H_{6\text{anti}}$), 1.51 (*d*, $J = 8.6$ Hz, 1H, $H_{6\text{syn}}$), 1.39 (*d*, $J = 8.7$ Hz, 1H, $H_{6\text{syn}}$); ^{13}C NMR (100 MHz, CDCl_3) δ 169.9 and 169.5, 165.6 and 165.3, 133.4 and 133.3, 129.6 and 129.5, 129.3 and 129.0, 128.5 and 128.4, 69.8 and 69.1, 64.0 and 60.3, 46.1 and 44.7, 42.2 and 41.0, 30.9 and 29.6, 21.6 and 21.4; HRMS m/z found 246.1125, calcd for $\text{C}_{14}\text{H}_{16}\text{NO}_3$ ($M + \text{H}$) 246.1125; ^1H NMR (400 MHz, D_2O) δ 7.93 (m, 2H, Bz), 7.68 (m, 1H, Bz), 7.51 (m, 2H, Bz), 4.86 (*dt*, $J = 6.8, 1.7$ Hz, 1H, H_1), 4.78 (m, 1H, H_5 and its conformer, some part of signal is under D_2O peak), 4.71 (*dt*, $J = 6.4, 1.7$ Hz, 1H, H_1), 3.62–3.36 (m, 2H, 2 H_3 and their conformers), 3.17 (m, 1H, H_4), 2.05 (*s*, 3H, Ac), 2.03 (*s*, 3H, Ac), 1.81 (m, 1H, $H_{6\text{anti}}$), 1.76 (m, 1H, $H_{6\text{anti}}$), 1.58 (*d*, $J = 9.1$ Hz, 1H, $H_{6\text{syn}}$), 1.49 (*d*, $J = 9.0$ Hz, 1H, $H_{6\text{syn}}$); NOE (500 MHz, CDCl_3) the major acetyl signal at δ 2.00 on irradiation enhances major H_1 at δ 4.50. The minor acetyl signal at δ 2.05 on irradiation enhances minor H_3 at δ 3.40; NOE (500 MHz, D_2O) the major acetyl signal at δ 2.03 on irradiation enhances the major H_1 at δ 4.71. The minor acetyl signal at δ 2.05 on irradiation enhances the minor H_3 at δ 3.60. $K_{\text{trans/cis}} = 64/36$ (CDCl_3); $K_{\text{trans/cis}} = 58/42$ (D_2O) based on $H_{6\text{syn}}$ peaks.

***N*-Acetyl-5-syn-hydroxy-2-azabicyclo[2.1.1]hexane (12b).** General Procedure for Benzoate Removal. Et_3N (770 μL , 5.504 mmol) was added to the benzoate **31** (27 mg, 0.110 mmol) in methanol (1 mL) and stirred at room temperature for 1 day under argon. After the solvent was removed in vacuo, the crude was chromatographed (prep TLC: 9:1 ethyl acetate/MeOH) to afford 11 mg (71%) of alcohol **12b** as an off-white solid: $R_f = 0.29$ (9:1 ethyl acetate/MeOH); mp 52–54 °C (ethyl acetate); ^1H NMR (400 MHz, CDCl_3) δ 4.60 (*dt*, $J = 6.8, 1.7$ Hz, 1H, H_1), 4.55 (*d*, $J = 4.2$ Hz, 1H, H_5), 4.27 (*bd*, $J = 6.9$ Hz, 1H, H_5), 4.16 (*dt*, $J = 6.6, 1.8$ Hz, 1H, H_1), 3.84 (m, 1H, OH), 3.50 (*brd*, $J = 7.9$ Hz, 1H, H_3), 3.46 (*brd*, $J = 9.8$ Hz, 1H, H_3), 3.27 (m, 1H, H_3' and its conformer), 2.78 (m, 1H, H_4 and its conformer), 2.05 (*s*, 3H, Ac), 2.04 (*s*, 3H, Ac), 1.39 (m, 1H, $H_{6\text{anti}}$), 1.34 (m, 1H, $H_{6\text{anti}}$), 1.23 (*d*, $J = 8.6$ Hz, 1H, $H_{6\text{syn}}$), 1.14 (*d*, $J = 8.6$ Hz, 1H, $H_{6\text{syn}}$); ^{13}C NMR (100 MHz, CDCl_3) δ 170.5 and 169.8, 70.1 and 68.9, 65.1 and 62.0, 46.1 and 44.1, 42.1 and 42.0, 29.6 and 28.6, 21.9 and 21.4; HRMS m/z found 164.0682, calcd for $\text{C}_7\text{H}_{11}\text{NO}_2$ Na ($M + \text{Na}$) 164.0682. ^1H NMR (400 MHz, D_2O) δ 4.55 (*dt*, $J = 6.7, 1.8$ Hz, 1H, H_1), 4.37 (*dt*, $J = 6.5, 1.8$ Hz, 1H, H_1), 3.95 (*bdd*, $J = 3.1, 1.8$

Hz, 1H, H₅), 3.93 (dd, *J* = 3.1, 1.8 Hz, 1H, H₅), 3.48 (s, 2H, H₃), 3.32 (two d, *J* = 9.8, 9.7 Hz, 2H, H₃), 2.84 (m, 1H, H₄ and its conformer), 2.09 (s, 3H, Ac), 2.08 (s, 3H, Ac), 1.51 (m, 1H, H_{6anti}), 1.45 (m, 1H, H_{6anti}), 1.29 (d, *J* = 8.8 Hz, 1H, H_{6syn}), 1.21 (d, *J* = 8.8 Hz, 1H, H_{6syn}); NOE (500 MHz, CDCl₃, some C₆D₆ added to resolve peaks) the minor H₁ signal at δ 4.16 on irradiation enhances the minor COCH₃ at δ 2.04 and vice versa; NOE (500 MHz, D₂O) the major H₁ resonance at δ 4.37 on irradiation enhances the major COCH₃ at δ 2.08. The minor H₃ resonance at δ 3.48 on irradiation enhances the minor COCH₃ at δ 2.09. *K*_{T/C} = 43/57 (CDCl₃) and *K*_{T/C} = 54/46 (D₂O) based on H_{6syn} peaks.

N-(Benzyloxycarbonyl)-5-anti-acetoxy-2-azabicyclo[2.1.1]hexane (33). According to the general procedure, AIBN (600 mg) and (TMS)₃SiH (10.45 mL, 33.8 mmol) were added to bromoacetate¹⁷ **32** (6.00 g, 16.9 mmol) in dry toluene (300 mL). The resulting solution was stirred vigorously at 70 °C for 3 h under an argon-filled balloon. Workup and chromatography (10% and then 25% ether in hexanes) afforded 3.52 g (76%) of acetate **33** as a light yellow oil at *R*_f = 0.44 (1:1 ether/hexanes): ¹H NMR (400 MHz, CDCl₃) δ 7.30–7.18 (m, 5H, Ph), 5.07 (s, 2H, OCH₂), 4.48 (d, *J* = 7.3 Hz, 1H, H₅), 4.34 (br dd, *J* = 7.1, 1.2 Hz, 1H, H₁), 3.43 (d, *J* = 9.0 Hz, 1H, H₃), 3.37 (d, *J* = 9.0 Hz, 1H, H₃), 2.78 (dd, *J* = 7.1, 2.8 Hz, 1H, H₄), 2.60 (br d, *J* = 8.1 Hz, 1H, H_{6anti}), 2.00 (s, 3H, COCH₃), 1.52 (dd, *J* = 8.1, 7.3 Hz, 1H, H_{6syn}); ¹³C NMR (100 MHz, CDCl₃) δ 170.4, 155.5 (br), 136.5, 128.2, 127.8, 127.6, 81.8, 65.6, 61.8 (br), 47.9, 42.4, 36.7, 24.9 and 20.6; HRMS *m/z* found 298.1060, calcd for C₁₅H₁₇NO₄Na (M + Na) 298.1055.

N-(Benzyloxycarbonyl)-5-anti-hydroxy-2-azabicyclo[2.1.1]hexane (34). According to the general procedure, Et₃N (15 mL, 0.109 mol) was added to acetate **33** (3.00 g, 0.011 mol) in methanol (270 mL) and the mixture stirred at rt for 12 h. Workup and chromatography (1:1 ethyl acetate/hexanes) afforded 2.20 g (87%) of alcohol **34** as a light yellow oil at *R*_f 0.50 (2:1 ethyl acetate/hexanes): ¹H NMR (300 MHz, CDCl₃) δ 7.38–7.25 (m, 5H), 5.12 (s, 2H), 4.42 (br, 1H, OH), 4.18 (dd, *J* = 7.2, 1.2 Hz, 1H, H₁), 4.03 (d, *J* = 7.1 Hz, 1H, H₅), 3.37 (s, 2H, H₃), 2.89 (br, 1H, H_{6anti}), 2.63 (dd, *J* = 7.2, 3.1 Hz, 1H, H₄), 1.60 (dd, *J* = 7.8, 7.1 Hz, 1H, H_{6syn}); ¹³C NMR (100 MHz, CDCl₃) δ 155.6, 136.6, 128.4, 127.9, 127.7, 80.9, 66.7, 63.6 and 63.2, 48.2 (br), 43.8, 36.7 (br); HRMS *m/z* found 256.0946, calcd for C₁₃H₁₅NO₃Na (M + Na) 256.0950.

N-(tert-Butoxycarbonyl)-5-anti-hydroxy-2-azabicyclo[2.1.1]hexane (13a). According to the general procedure, (Boc)₂O (954 mg, 4.37 mmol) and Pd(OH)₂ (150 mg) were added to alcohol **34** (1.00 g, 4.28 mmol) in methanol (40 mL) and stirred at rt for 2 h under a H₂-filled balloon. Workup and chromatography (1:2 ethyl acetate/hexanes) afforded 733 mg (86%) of alcohol **13a** as an off-white solid: *R*_f = 0.32 (2:3 ethyl acetate/hexanes); mp 113–114 °C; ¹H NMR (400 MHz, CDCl₃) δ 4.07 (br d, *J* = 7.3 Hz, 1H, H₁), 4.03 (br d, *J* = 6.8 Hz, 1H, H₅), 3.66 (br, 1H, OH), 3.29 (s, 2H, H₃), 2.86 (br, 1H, H_{6anti}), 2.61 (br d, *J* = 6.8 Hz, 1H, H₄), 1.57 (dd, *J* = 7.3, 7.3 Hz, 1H, H_{6syn}), 1.43 (s, 9H, Boc); ¹³C NMR (100 MHz, CDCl₃) δ 155.7, 81.0, 79.6, 63.8 and 62.9 (br), 48.6 and 48.0 (br), 43.9, 36.8, 28.4; HRMS *m/z* found 222.1104, calcd for C₁₀H₁₇NO₃Na (M + Na) 222.1104.

N-(tert-Butoxycarbonyl)-5-anti-benzoyloxy-2-azabicyclo[2.1.1]hexane (35). Alcohol **34** (85 mg, 0.427 mmol) was dissolved in dry CH₂Cl₂ (5 mL) under argon. The reaction mixture was cooled to 0 °C and sequentially treated with triethylamine (300 μL, 2.133 mmol), DMAP (57 mg, 0.469 mmol), and benzoyl chloride (125 μL, 1.067 mmol). The mixture was stirred for 30 min at 0 °C, allowed to come to room temperature, and then stirred for 3 h. The solution was washed with water (3 × 2 mL), and the combined organic layers were dried and evaporated to dryness. The residue was purified by chromatography on silica gel (10% ethyl acetate in hexanes) to afford 119 mg (92%) of benzoate **35** as a light orange oil: *R*_f = 0.54 (4:1 hexanes/ethyl acetate); ¹H NMR (400 MHz, CDCl₃) δ 8.09–8.03 (m, 2H), 7.62–7.56 (m, 1H), 7.50–7.43 (m, 2H), 4.81 (d, *J* = 7.3 Hz, 1H, H₅), 4.45 (br,

1H, H₁), 3.53 (br d, *J* = 9.0 Hz, 1H, H₃), 3.45 (br d, *J* = 9.0 Hz, 1H, H₃), 2.99 (dd, *J* = 7.2, 2.8 Hz, 1H, H₄), 2.79 (d, *J* = 8.1 Hz, 1H, H_{6anti}), 1.67 (dd, *J* = 8.1, 7.3 Hz, 1H, H_{6syn}), 1.49 (s, 9H); ¹³C NMR (100 MHz, CDCl₃) δ 166.3, 155.6, 133.3, 129.8, 129.6 and 128.5, 82.6, 79.8, 62.2, 48.2, 43.0, 37.1, 28.5; HRMS *m/z* found 326.1367, calcd for C₁₇H₂₁NO₄Na (M + Na) 326.1363.

N-Acetyl-5-anti-benzoyloxy-2-azabicyclo[2.1.1]hexane (36). To a solution of carbamate **35** (108 mg, 0.356 mmol) in dry CH₂Cl₂ (10 mL) was added TFA (275 μL, 3.559 mmol) at rt. The solution was stirred for 6 h at room temperature under argon, and then solvent was removed in vacuo to afford the 173 mg of crude amine as an orange oil. To the crude amine in dry CH₂Cl₂ (15 mL) was added DMAP (130 mg, 1.068 mmol) under argon, and the solution was cooled to 0 °C. AcCl (75 μL, 1.068 mmol) was added to the reaction mixture that was maintained for 30 min at 0 °C and then brought to rt. After being stirred for 4 h at rt, the reaction mixture was washed with water (2 × 5 mL) and then the combined aqueous layer was backwashed with CH₂Cl₂ (4 mL). The organic layer was dried over Na₂SO₄ and filtered, and the solvent was removed in vacuo. The crude (122 mg) was chromatographed (prep tlc, 1:9 hexanes/ethyl acetate) to afford 67 mg (77%) of amide **36** as a light orange oil: *R*_f = 0.22 (1:9 hexanes/ethyl acetate); ¹H NMR (400 MHz, CDCl₃) δ 8.06–8.01 (m, 2H), 7.61–7.55 (m, 1H), 7.48–7.42 (m, 2H), 4.89 (dd, *J* = 7.4, 1.8 Hz, 1H, H₁), 4.77 (d, *J* = 7.3 Hz, 1H, H₅), 4.76 (d, *J* = 7.3 Hz, 1H, H₅), 4.41 (dd, *J* = 7.0, 1.8 Hz, 1H, H₁), 3.65–3.51 (m, 2H, 2H₃), 3.06 (m, 1H, H₄), 2.84 (m, 1H, H_{6anti}), 2.10 (s, 3H), 2.05 (s, 3H), 1.72 (dd, *J* = 8.3, 7.3 Hz, 1H, H_{6syn}), 1.65 (dd, *J* = 8.3, 7.3 Hz, 1H, H_{6syn}); ¹³C NMR (100 MHz, CDCl₃) δ 168.7 and 168.5, 166.2 and 166.1, 133.4 and 133.3, 129.6 (2C), 128.5 and 128.4, 82.4 and 82.0, 63.8 and 60.4, 49.0 and 47.1, 43.1 and 42.0, 37.6 and 36.7, 21.6 and 20.9; HRMS *m/z* found 246.1125, calcd for C₁₄H₁₆NO₃ (M + H) 246.1125.

N-Acetyl-5-anti-hydroxy-2-azabicyclo[2.1.1]hexane (13b). Et₃N (450 μL, 3.180 mmol) was added to the benzoate **36** (52.0 mg, 0.212 mmol) in methanol (5 mL) and stirred at room temperature for 17 h under argon. After the solvent was removed in vacuo, the crude was chromatographed (9:1 ethyl acetate/MeOH) to afford 23.6 mg (79%) of alcohol **13b** as a colorless oil: *R*_f = 0.26 (9:1 ethyl acetate/MeOH); ¹H NMR (400 MHz, CDCl₃) δ 4.69 (br, 1H, OH), 4.48 (dd, *J* = 7.3, 1.7 Hz, 1H, H₁), 4.05 (d, *J* = 7.0 Hz, 1H, H₅), 4.04 (dd, *J* = 7.0, 1.9 Hz, 1H, H₁), 3.98 (d, *J* = 7.0 Hz, 1H, H₅), 3.40 (s, 2H, H₃), 3.37 (s, 2H, H₃), 2.94 (br dd, *J* = 8.1, 8.1 Hz, 1H, H_{6anti}), 2.71 (dd, *J* = 7.1, 3.2 Hz, 1H, H₄), 2.67 (dd, *J* = 7.0, 3.3 Hz, 1H, H₄), 2.01 (s, 3H, COCH₃), 1.98 (s, 3H, COCH₃), 1.62 (dd, *J* = 8.0, 7.0 Hz, 1H, H_{6syn}), 1.55 (dd, *J* = 8.0, 7.0 Hz, 1H, H_{6syn}); ¹³C NMR (100 MHz, CDCl₃) δ 168.9 and 168.3, 80.9 and 80.5, 65.5 and 62.3, 49.4 and 47.6, 43.8 and 43.4, 37.3 and 36.3, 21.4 and 20.8; HRMS *m/z* found 164.0692, calcd for C₁₇H₁₉NO₂Na (M + Na) 164.0687. ¹H NMR (400 MHz, D₂O) δ 4.46 (dd, *J* = 7.3, 1.8 Hz, 1H, H₁), 4.29 (dd, *J* = 7.1, 1.9 Hz, 1H, H₁), 4.08 (d, *J* = 7.1 Hz, 1H, H₅), 4.05 (d, *J* = 7.1 Hz, 1H, H₅), 3.61 (s, 2H, 2H₃), 3.42 (s, 2H, 2H₃), 2.88 (m, 1H, H₄), 2.78 (m, 1H, H_{6anti}), 2.09 (s, 3H, COCH₃), 2.06 (s, 3H, COCH₃), 1.74 (dd, *J* = 7.5, 7.1 Hz, 1H, H_{6syn}), 1.68 (dd, *J* = 7.5, 7.1 Hz, 1H, H_{6syn}); NOE (CDCl₃) the major acetyl signal at δ 2.01 on irradiation sees the major H₁ at δ 4.04. The minor acetyl signal at δ 1.98 on irradiation sees the minor H₃ at δ 3.40. NOE (D₂O): the major acetyl signal at δ 2.09 on irradiation enhances the major H₁ at δ 4.29. The minor acetyl signal at δ 2.06 on irradiation enhances the minor H₃ at δ 3.61. *K*_{T/C} = 50.5/49.5 (CDCl₃) based on H_{6syn} and 54/46 (D₂O) based on H₁.

N-Acetyl-5-anti-benzoyloxy-2-azabicyclo[2.1.1]hexane (36): ¹H NMR (400 MHz, D₂O) δ 8.14–8.09 (m, 2H), 7.77–7.71 (m, 1H), 7.62–7.56 (m, 2H), 4.80 (m, 2H, H₅ and H₁ rotamer are under D₂O peak), 4.66 (dd, *J* = 7.0, 1.7 Hz, 1H, H₁), 3.80 (d, *J* = 9.1 Hz, 1H, H₃), 3.75 (d, *J* = 9.1 Hz, 1H, H₃), 3.61 (d, *J* = 9.9 Hz, 1H, H₃), 3.56 (d, *J* = 9.9 Hz, 1H, H₃), 3.16 (m, 1H, H₄), 2.96 (m, 2H, H_{6anti} both conformers), 2.17 (s, 3H), 2.13 (s, 3H), 1.81 (dd, *J* = 8.0, 8.0 Hz, 1H, H_{6syn}), 1.75 (dd, *J* =

8.0, 8.0 Hz, 1H, $H_{6,5\text{syn}}$); NOE (CDCl_3) the major acetyl signal at δ 2.10 on irradiation sees the major H_1 at δ 4.41 and vice versa. The minor H_1 signal at δ 4.89 on irradiation sees no proton. NOE (D_2O): the major acetyl signal at δ 2.17 on irradiation enhances the major H_1 at δ 4.66. The minor acetyl signal at δ 2.13 on irradiation enhances the H_3 signal δ 3.80 and the H_3 signal δ 3.75. $K_{\text{T/C}} = 61/39$ (CDCl_3) based on H_1 and 56/44 (D_2O) based on H_3 .

■ ASSOCIATED CONTENT

S Supporting Information. Coordinates of optimized geometries, selected angles, and energy calculations for **9** and **10b–13b**; data from the X-ray diffraction analysis of *syn*-alcohol **12b**, copies of ^1H NMR, ^{13}C NMR, and ^{19}F NMR for new compounds. This material is available free of charge via the Internet at <http://pubs.acs.org>.

■ AUTHOR INFORMATION

Corresponding Author

*E-mail: grkrow@temple.edu.

■ ACKNOWLEDGMENT

Financial support was provided by the National Science Foundation (CHE 0515635) and (DGE-0841377). M.D.S. was supported by an American Chemical Society Division of Medicinal Chemistry graduate fellowship; M.S. was supported by a Der Min Fan Fellowship. We thank Alex Shaffer and Zilun Hu for assistance and Hans Reich and David Dalton for helpful discussions.

■ REFERENCES

- (a) Lu, K. P.; Finn, G.; Lee, T. H.; Nicholson, L. *Nat. Chem. Biol.* **2007**, *3*, 619–629. (b) Dugave, C.; Demange, L. *Chem. Rev.* **2003**, *103*, 2475–2532. (c) Fischer, G. *Chem. Soc. Rev.* **2000**, *29*, 119–127. (d) Andreotti, A. H. *Biochemistry* **2003**, *42*, 9515–9542. (e) Wedemeyer, W. J.; Welker, E.; Scheraga, H. A. *Biochemistry* **2002**, *41*, 14637–14644.
- (a) Lummis, S. C. R.; Beene, D. L.; Lee, L. W.; Lester, H. A.; Broadhurst, R. W.; Dougherty, D. A. *Nature* **2005**, *438*, 248–252. (b) Lin, L.-N.; Brandts, J. F. *Biochemistry* **1979**, *18*, 43–47.
- (a) For a review of prolines and collagen, see: Shoulders, M. D.; Raines, R. T. *Annu. Rev. Biochem.* **2009**, *78*, 929–958. (b) Shoulders, M. D.; Satyshur, K. A.; Forest, K. T.; Raines, R. T. *Proc. Natl. Acad. Sci. U.S.A.* **2010**, *107*, 559–564.
- (a) Eberhardt, E. S.; Panasik, N., Jr.; Raines, R. T. *J. Am. Chem. Soc.* **1996**, *118*, 12261–12266. (b) DeRider, M. L.; Wilkens, S. J.; Waddell, M. J.; Bretscher, L. E.; Weinhold, F.; Raines, R. T.; Markley, J. L. *J. Am. Chem. Soc.* **2002**, *124*, 2497–2505. (c) Kuemin, M.; Nagel, Y. A.; Schweizer, S.; Monnard, F. W.; Ochsenfeld, C.; Wennemers, H. *Angew. Chem., Int. Ed.* **2010**, *49*, 1–5. (d) Bretscher, L. E.; Jenkins, C. L.; Taylor, K. M.; DeRider, M. L.; Raines, R. T. *J. Am. Chem. Soc.* **2001**, *123*, 777–778. (e) Renner, C.; Alefelder, S.; Bae, J. H.; Budisa, N.; Huber, R.; Moroder, L. *Angew. Chem., Int. Ed.* **2001**, *40*, 923–925. (f) Hodges, J. A.; Raines, R. T. *J. Am. Chem. Soc.* **2003**, *125*, 9262–9263. (g) Doi, M.; Nishi, Y.; Uchiyama, S.; Nishiuchi, Y.; Nakazawa, T.; Ohkubo, T.; Kobayashi, Y. *J. Am. Chem. Soc.* **2003**, *125*, 9922–9923. (h) Hodges, J. A.; Raines, R. T. *J. Am. Chem. Soc.* **2005**, *127*, 15923–15932. (i) Kim, W.; McMillan, R. A.; Snyder, J. P.; Conticello, V. P. *J. Am. Chem. Soc.* **2005**, *127*, 18121–18132. (j) Doi, M.; Nishi, Y.; Uchiyama, S.; Nishiuchi, Y.; Nishio, H.; Nakazawa, T.; Ohkubo, T.; Kobayashi, Y. *J. Pept. Sci.* **2005**, *11*, 609–616. (k) Horng, J.-C.; Raines, R. T. *Protein Sci.* **2006**, *15*, 74–83. (l) Kim, W.; Hardcastle, K. I.; Conticello, V. P. *Angew. Chem., Int. Ed.* **2006**, *45*, 8141–8145. (m) Shoulders, M. D.; Kamer, K. J.; Raines, R. T. *Bioorg. Med. Chem. Lett.* **2009**, *19*, 3859–3862. (n) Kubik, S.; Goddard, R. *Proc. Natl. Acad. Sci. U.S.A.* **2002**, *99*, 5127–5132. (o)

Buechter, D. D.; Paolella, D. N.; Leslie, B. S.; Brown, M. S.; Mehos, K. A.; Gruskin, E. A. *J. Biol. Chem.* **2003**, *278*, 645–650. (p) Mizuno, K.; Hayashi, T.; Bachinger, H. P. *J. Biol. Chem.* **2003**, *278*, 32373–32379. (q) Gauba, V.; Hartgerink, J. D. *J. Am. Chem. Soc.* **2007**, *129*, 15034–15041. (r) Gauba, V.; Hartgerink, J. D. *J. Am. Chem. Soc.* **2008**, *130*, 7509–7515. (s) Gauba, V.; Hartgerink, J. D. *J. Am. Chem. Soc.* **2007**, *129*, 2683–2690. (t) Erdmann, R. S.; Wennemers, J. *Am. Chem. Soc.* **2010**, *132*, 13957–13959. (u) Rele, S.; Song, Y.; Apkarian, R. P.; Zheng, Q.; Conticello, V. P.; Chaikof, E. L. *J. Am. Chem. Soc.* **2007**, *129*, 14780–14787.

(5) For derivatized hydroxyprolines, see: (a) Jenkins, C. L.; McCloskey, A. I.; Guzei, I. A.; Eberhardt, E. S.; Raines, R. T. *Biopolymers: Pept. Sci.* **2005**, *80*, 1–8. (b) Owens, N. W.; Braun, C.; O'Neill, J. D.; Marat, K.; Schweizer, F. *J. Am. Chem. Soc.* **2007**, *129*, 11670–11671. (c) Bann, J. G.; Bachinger, H. P. *J. Biol. Chem.* **2000**, *275*, 24466–24469. (d) Kotch, F. W.; Guzei, I. A.; Raines, R. T. *J. Am. Chem. Soc.* **2008**, *130*, 2952–2953. (e) Naduthambi, D.; Zondlo, N. J. *J. Am. Chem. Soc.* **2006**, *128*, 12430–12431. (f) Thomas, K. M.; Naduthambi, D.; Triyari, G.; Zondlo, N. J. *Org. Lett.* **2005**, *7*, 2397–2400. (g) Owens, N. W.; Lee, A.; Marat, K.; Schweizer, F. *Chem.—Eur. J.* **2009**, *15*, 10649–10657.

(6) For prolines other than 4-F or 4-OH, see: (a) Mollica, A.; Paradisi, M. P.; Varani, K.; Spisani, S.; Lucente, G. *Bioorg. Med. Chem.* **2006**, *14*, 2253–2265. (b) Cadamuro, S. A.; Reichhold, R.; Kusebauch, U.; Musiol, H.-J.; Renner, C.; Tavan, P.; Moroder, L. *Angew. Chem., Int. Ed.* **2008**, *47*, 2143–2146. (c) Babu, I. R.; Ganesh, K. N. *J. Am. Chem. Soc.* **2001**, *123*, 2079–2080. (d) Beausoleil, E.; Sharma, R.; Michnick, W. W.; Lubell, W. D. *J. Org. Chem.* **1998**, *63*, 6572–6578. (e) Curran, T. P.; Chandler, N. M.; Kennedy, R. J.; Keaney, M. T. *Tetrahedron Lett.* **1996**, *37*, 1933–1936. (f) Kumin, M.; Sonntag, L.-S.; Wennemers, H. *J. Am. Chem. Soc.* **2007**, *129*, 466–467. (g) Shoulders, M. D.; Hodges, J. A.; Raines, R. T. *J. Am. Chem. Soc.* **2006**, *128*, 8112–8113. (h) Sonntag, L.-S.; Schweizer, S.; Ochsenfeld, C.; Wennemers, H. *J. Am. Chem. Soc.* **2006**, *128*, 14697–14703. (i) Shoulders, M. D.; Guzei, I. A.; Raines, R. T. *Biopolymers* **2008**, *89*, 443–454. (j) Koskinen, A. M. P.; Heliaja, J.; Kumpulainen, E. T. T.; Koivisto, J.; Manisikkamacki, H.; Rissanen, K. *J. Org. Chem.* **2005**, *70*, 6447–6453.

(7) Giacovazzo, C.; Monaco, H. L.; Artioli, G.; Viterbo, D.; Ferraris, G.; Gilli, G.; Zanotti, G.; Catti, M. *Fundamentals of Crystallography*, 2nd ed.; Oxford University Press: Oxford, UK, 2002; pp 492–499.

(8) Holmgren, S. K.; Taylor, K. M.; Bretscher, L. E.; Raines, R. T. *Nature* **1998**, *392*, 666–667.

(9) (a) Jenkins, C. L.; Lin, G.; Duo, J.; Rapolu, D.; Guzei, I. A.; Raines, R. T.; Krow, G. R. *J. Org. Chem.* **2004**, *69*, 8565–8573.

(10) Krow, G. R.; Herzon, S. B.; Lin, F.; Qiu, G.; Sonnet, P. E. *Org. Lett.* **2002**, *4*, 3151–3154.

(11) (a) Sunose, M.; Peakman, T. M.; Charmant, J. P. H.; Gallagher, T.; Macdonald, S. J. F. *J. Chem. Soc., Chem. Commun.* **1998**, 1723–1724. (b) Pandey, G.; Chakrabarti, D. *Tetrahedron Lett.* **1996**, *37*, 2285–2288.

(12) Krow, G. R.; Lin, G.; Yu, F.; Sonnet, P. E. *Org. Lett.* **2003**, *5*, 2739–2741.

(13) (a) Gandon, L. A.; Russell, A. G.; Guveli, T.; Brodewolf, A. E.; Kariuki, B. M.; Spencer, N.; Snaith, J. S. *J. Org. Chem.* **2006**, *71*, 5198–5207. (b) Khazanchi, R.; Yu, P. L.; Johnson, F. *J. Org. Chem.* **1993**, *58*, 2552–2556.

(14) Krow, G. R.; Lin, G.; Rapolu, D.; Fang, Y.; Lester, W. S.; Herzon, S. B.; Sonnet, P. E. *J. Org. Chem.* **2003**, *68*, 5292–5299.

(15) (a) Alvernhe, G.; Laurent, A.; Haufe, G. *Synthesis* **1987**, 562–564. (b) Shellhamer, D. F.; Horney, M. J.; Pettus, B. J.; Pettus, T. L.; Stringer, J. M.; Heasley, V. L.; Syret, R. G.; Dobroldky, J. M., Jr. *J. Org. Chem.* **1999**, *64*, 1094–1098.

(16) Krow, G. R.; Huang, Q.; Lin, G.; Centafont, R. R.; Thomas, A. M.; Gandla, D.; DeBrosse, C.; Carroll, P. J. *J. Org. Chem.* **2006**, *71*, 2090–2098.

(17) Krow, G. R.; Lee, Y. B.; Lester, W. S.; Christian, H.; Shaw, D. A.; Yuan, J. *J. Org. Chem.* **1998**, *63*, 8558–8560.

(18) Pichlmair, S.; Ruiz, M. D. L.; Vilotijevic, I.; Paquette, L. A. *Tetrahedron* **2006**, *62*, 5791–5802.